Autolus Therapeutics

1.31
-0.09 (-6.43%)
At close: Apr 25, 2025, 3:59 PM
1.36
3.42%
After-hours: Apr 25, 2025, 05:36 PM EDT

Autolus Therapeutics Statistics

Share Statistics

Autolus Therapeutics has 266.13M shares outstanding. The number of shares has increased by 0.03% in one year.

Shares Outstanding 266.13M
Shares Change (YoY) 0.03%
Shares Change (QoQ) 0%
Owned by Institutions (%) 63.25%
Shares Floating 240.32M
Failed to Deliver (FTD) Shares 2.81K
FTD / Avg. Volume 0.19%

Short Selling Information

The latest short interest is 9.91M, so 3.72% of the outstanding shares have been sold short.

Short Interest 9.91M
Short % of Shares Out 3.72%
Short % of Float 4.91%
Short Ratio (days to cover) 7.33

Valuation Ratios

The PE ratio is -2.72 and the forward PE ratio is -2.09. Autolus Therapeutics's PEG ratio is 0.1.

PE Ratio -2.72
Forward PE -2.09
PS Ratio 59.25
Forward PS 0.5
PB Ratio 1.4
P/FCF Ratio -2.91
PEG Ratio 0.1
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Autolus Therapeutics.

EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 10.88, with a Debt / Equity ratio of 0.12.

Current Ratio 10.88
Quick Ratio 10.81
Debt / Equity 0.12
Debt / EBITDA -0.26
Debt / FCF -0.26
Interest Coverage -25.98

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity n/a
Return on Assets n/a
Return on Invested Capital n/a
Revenue Per Employee $15.64K
Profits Per Employee $-341.05K
Employee Count 647
Asset Turnover 0.01
Inventory Turnover 2.75

Taxes

Income Tax 1.53M
Effective Tax Rate -0.7%

Stock Price Statistics

The stock price has increased by -65.93% in the last 52 weeks. The beta is 2.06, so Autolus Therapeutics's price volatility has been higher than the market average.

Beta 2.06
52-Week Price Change -65.93%
50-Day Moving Average 1.69
200-Day Moving Average 3
Relative Strength Index (RSI) 44.66
Average Volume (20 Days) 1.52M

Income Statement

In the last 12 months, Autolus Therapeutics had revenue of 10.12M and earned -220.66M in profits. Earnings per share was -0.86.

Revenue 10.12M
Gross Profit -1.27M
Operating Income -241.43M
Net Income -220.66M
EBITDA -202.12M
EBIT -209.84M
Earnings Per Share (EPS) -0.86
Full Income Statement

Balance Sheet

The company has 227.38M in cash and 52.63M in debt, giving a net cash position of 174.75M.

Cash & Cash Equivalents 227.38M
Total Debt 52.63M
Net Cash 174.75M
Retained Earnings -1.1B
Total Assets 782.73M
Working Capital 600.19M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -206.27M and capital expenditures 0, giving a free cash flow of -206.27M.

Operating Cash Flow -206.27M
Capital Expenditures 0
Free Cash Flow -206.27M
FCF Per Share -0.81
Full Cash Flow Statement

Margins

Gross margin is -12.52%, with operating and profit margins of -2385.63% and -2180.45%.

Gross Margin -12.52%
Operating Margin -2385.63%
Pretax Margin -2165.36%
Profit Margin -2180.45%
EBITDA Margin -1997.27%
EBIT Margin -2385.63%
FCF Margin -2038.25%

Dividends & Yields

AUTL does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield n/a
FCF Yield n/a
Dividend Details

Analyst Forecast

The average price target for AUTL is $10, which is 619.4% higher than the current price. The consensus rating is "Buy".

Price Target $10
Price Target Difference 619.4%
Analyst Consensus Buy
Analyst Count 5
Stock Forecasts

Scores

Altman Z-Score -1.27
Piotroski F-Score 4